{"id":891,"date":"2013-10-01T12:06:00","date_gmt":"2013-10-01T10:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2013\/die-hersteller-der-neuen-antikoagulanzien-warnen-vor-blutungen-und-unsachgemaessem-gebrauch"},"modified":"2013-10-01T12:06:00","modified_gmt":"2013-10-01T10:06:00","slug":"die-hersteller-der-neuen-antikoagulanzien-warnen-vor-blutungen-und-unsachgemaessem-gebrauch","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2013\/die-hersteller-der-neuen-antikoagulanzien-warnen-vor-blutungen-und-unsachgemaessem-gebrauch","title":{"rendered":"Die Hersteller der neuen Antikoagulanzien warnen vor Blutungen und unsachgem\u00e4\u00dfem Gebrauch"},"content":{"rendered":"<p>Im September haben deutsche und \u00f6sterreichische \u00c4rzte ungew\u00f6hnliche Post erhalten. Die Medical Directors von Bristol-Myers Squibb, Pfizer, Boehringer-Ingelheim und Bayer weisen in einem gemeinsamen Brief auf das Blutungsrisiko ihrer Arzneimittel Dabigatran (Pradaxa\u00ae), Rivaroxaban (Xarelto\u00ae) und Apixaban (Eliquis\u00ae) hin. Die Hersteller dieser neuen (direkten) oralen Antikoagulanzien (NOAK) teilen den \u00c4rzten mit, dass \u201eklinische Studien und Meldungen [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Im September haben deutsche und \u00f6sterreichische \u00c4rzte ungew\u00f6hnliche Post erhalten. Die Medical Directors von Bristol-Myers Squibb, Pfizer, Boehringer-Ingelheim und Bayer weisen in einem gemeinsamen Brief auf das Blutungsrisiko ihrer Arzneimittel Dabigatran (Pradaxa\u00ae), Rivaroxaban (Xarelto\u00ae) und Apixaban (Eliquis\u00ae) hin. Die Hersteller dieser neuen (direkten) oralen Antikoagulanzien (NOAK) teilen den \u00c4rzten mit, dass \u201eklinische Studien und Meldungen [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[137,1322,1414,2305,1314,1312,1328,1327,2304],"class_list":["post-891","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-antikoagulanzien","tag-apixaban","tag-blutungen","tag-dabigatran","tag-direkte-orale-antikoagulanzien","tag-doak","tag-neue-orale-antikoagulanzien","tag-noak","tag-rivaroxaban"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/891","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=891"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/891\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=891"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=891"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=891"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}